Schweiz
bioMérieux VIRTUO™, the new generation of blood culture system, is CE-marked
23 Juli, 2014
Marcy l'Etoile, France, July 23, 2014 - bioMérieux, a world leader in the field of in vitro diagnostics, announces that VIRTUO™, the new generation of BacT/ALERT®, has been CE-marked. This uniquely innovative automated blood culture microbial detection system further enriches the offering of the BacT/ALERT® product range and is now commercially available in targeted countries that recognize CE marking. The enhanced performance of the system will help laboratories provide rapid results to clinicians to help maximize laboratory efficiency and facilitate better patient outcomes.
bioMérieux strengthens its Clostridium difficile offer with the launch of VIDAS® C. difficile GDH
26 Februar, 2014
bioMérieux, a world leader in the field of in vitro diagnostics, is pleased to announce that the launch of VIDAS® C. difficile GDH makes it the only company with the width to provide solutions for C. difficile according to different laboratory settings, patient conditions and medical needs.
BioFire Submits 510(k) Application to FDA for FilmArray® Gastrointestinal Panel
19 Februar, 2014
BioFire Diagnostics, LLC today announced that it has submitted the FilmArray Gastrointestinal (GI) Panel to the U.S. Food and Drug Administration (FDA) for 510(k) clearance. The comprehensive FilmArray GI Panel tests for over 20 common bacteria, viruses and parasites that cause infectious diarrhea.
bioMérieux finalizes acquisition of the U.S. company BioFire, specialized in molecular biology
16 Januar, 2014
bioMérieux, a world leader in the field of in vitro diagnostics, announces that it has finalized its acquisition of 100% ownership in BioFire Diagnostics Inc., a privately held U.S.-based company specialized in molecular biology. The agreement to purchase BioFire was first announced on September 4.
bioMérieux is Moving Forward to a New Molecular Biology Workflow Solution for Reference or Centralized Laboratories
05 Dezember, 2013
bioMérieux, a world leader in the field of in vitro diagnostics, has announced that it is moving a new step forward to its comprehensive automation solution dedicated for reference or centralized molecular biology laboratories. As a key component of this modular automation solution, bioMérieux has selected Life Technologies’ 7500 instrument range as its preferred thermocyclers (Applied Biosystems® 7500, 7500 Fast and 7500 Fast Dx instruments).
bioMérieux launches the Parvovirus B19 R-gene® kit, a new ARGENE® test for the detection and quantification of the three Parvovirus B19 genotypes
29 Oktober, 2013
bioMérieux, a world leader in the field of in vitro diagnostics, has announced the launch of the Parvovirus B19 R-gene® kit, a new CE-marked ARGENE® real-time PCR test, used for the detection and quantification of the three Parvovirus B19 genotypes.
bioMérieux launches a new assay for vitamin D testing: VIDAS® 25 OH Vitamin D Total
30 September, 2013
bioMérieux, a world leader in the field of in vitro diagnostics, has announced the launch of VIDAS® 25 OH Vitamin D Total for the measurement of total vitamin D levels in human serum and plasma.
bioMérieux makes a significant acquisition in molecular biology in the U.S.
03 September, 2013
bioMérieux, a world leader in the field of in vitro diagnostics, announces that it has entered into an agreement to acquire BioFire Diagnostics Inc., a privately held U.S.-based company specialized in molecular biology. BioFire invented, manufactures and commercializes its multiplex PCR FilmArray® system, a simple and rapid molecular biology solution dedicated to the diagnosis of infectious diseases. Thanks to its syndromic approach to the diagnosis of these diseases, FilmArray® contributes to improving patient care and reducing healthcare spending. By further stimulating sales of this system and expanding its menu, bioMérieux intends to strengthen the Company’s position as a major player in infectious disease diagnostics, its core strategic focus.